



Understanding determinants of carbohydrate metabolism and their contribution to metabolic health; the impact of AMY1 CNV (P21-015-19)

O'Callaghan, Nathan; Valsesia, Armand; Kulkarni, Sameer; Marquis, Julien; Leone, Patricia; Mironova, Polina; Walter, Ondine; Saris, Wim; Descombes, Patrick; Hager, Jorg; Astrup, Arne; Darimont, Chrstian

Published in:
Current Developments in Nutrition

DOI:
[10.1093/cdn/nzz041.P21-015-19](https://doi.org/10.1093/cdn/nzz041.P21-015-19)

Publication date:
2019

Document version
Publisher's PDF, also known as Version of record

Document license:
[Other](#)

Citation for published version (APA):
O'Callaghan, N., Valsesia, A., Kulkarni, S., Marquis, J., Leone, P., Mironova, P., Walter, O., Saris, W., Descombes, P., Hager, J., Astrup, A., & Darimont, C. (2019). Understanding determinants of carbohydrate metabolism and their contribution to metabolic health; the impact of AMY1 CNV (P21-015-19). *Current Developments in Nutrition*, 3(Suppl. 1), 1848. <https://doi.org/10.1093/cdn/nzz041.P21-015-19>

Understanding Determinants of Carbohydrate Metabolism and Their Contribution to Metabolic Health; The Impact of AMY1 CNV (P21-015-19)

Nathan O'Callaghan,¹ Armand Valsesia,² Sameer Kulkarni,³ Julien Marquis,³ Patricia Leone,³ Polina Mironova,³ Ondine Walter,³ Wim Saris,⁴ Patrick Descombes,³ Jorg Hager,³ Wim Saris,⁴ Arne Astrup,⁴ and Christian Darimont³

¹CSIRO; ²Nestle Research; ³Nestle Research Centre; and ⁴University of Copenhagen

Objectives: Salivary α -amylase (AMY1) is responsible for the breakdown of starch into oligosaccharides, tri and di-saccharides giving a start to the starch digestion in the oral cavity on food consumption. Several studies recently reported contradicting results regarding the link between AMY1 copy numbers (CNs) and obesity and type 2 diabetes.

Objective: We investigated whether CN in the *AMY1* gene was associated with differential anthropometrics and glycaemic outcomes in obese individuals who underwent a dietary plan varying in macronutrient intake, as a part of weight loss and weight maintenance program. We also investigated whether there existed an interaction between nutrient intakes and *AMY1* CNs and if *AMY1* CNs have influence on body weight, body composition and glycaemic trajectories during dietary interventions.

Methods: Using the Paralogue Ratio Test, we accurately measured the *AMY1* CNs in 761 obese individuals from the Diogenes study.

Subjects underwent first an 8-week low-caloric diet (LCD, at 800 kcal/d) and those achieving >8% weight loss were then randomized to a 6-month weight maintenance dietary (WMD) intervention. The association between *AMY1* CNs and weight- and glycaemic- parameters was tested at baseline and following each intervention phase (LCD, WMD) with the use of linear mixed effect models adjusting for gender, age, center and total energy intake.

Results: At baseline, a modest association between *AMY1* CN and BMI ($P = 0.04$) was observed. *AMY1* CN was not associated with baseline glycaemic variables. Additionally, *AMY1* CN was not associated with anthropometric or glycaemic-outcomes following either LCD or WMD. Interaction analyses between *AMY1* CN and nutrient intake did not reveal significant association with any clinical parameters (at baseline and following LCD or WMD) or when testing gene x WMD interactions during the WMD phase

Conclusions: In the absence of association with weight trajectories or glycaemic improvements, the *AMY1* CN cannot be considered as an important biomarker for response to a clinical weight loss and weight maintenance programs in overweight/obese subjects.

Funding Sources: European Commission, Food Quality and Safety Priority of the Sixth Framework Program (FP6-2005-513946), Nestlé Institute of Health Sciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.